158 related articles for article (PubMed ID: 28700482)
1. Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3-4): A randomized placebo-controlled clinical trial.
Li S; Rao XR; Dai XW; Pei K; Wang L; Huo BM; Wang XJ; Kong LX; Zhang NN; Lian FM
Medicine (Baltimore); 2017 Jul; 96(28):e7448. PubMed ID: 28700482
[TBL] [Abstract][Full Text] [Related]
2. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Arita K; Kato A; Shimizu M
J Am Soc Nephrol; 2015 Jul; 26(7):1732-46. PubMed ID: 25349205
[TBL] [Abstract][Full Text] [Related]
3. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Kikuchi M; Shobu Y
Clin Exp Nephrol; 2018 Apr; 22(2):299-308. PubMed ID: 28741050
[TBL] [Abstract][Full Text] [Related]
6. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Yiqi Peiyuan granules for improving the short-term prognosis of patients with acute kidney injury: A multicenter, double-blind, placebo-controlled, randomized trial.
Wu JJ; Zhang TY; Qi YH; Zhu MY; Fang Y; Qi CJ; Cao LO; Lu JF; Lu BH; Tang LM; Shen JX; Mou S
J Integr Med; 2024 May; 22(3):279-285. PubMed ID: 38688809
[TBL] [Abstract][Full Text] [Related]
8. Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial.
Wang YJ; He LQ; Sun W; Lu Y; Wang XQ; Zhang PQ; Wei LB; Cao SL; Yang NZ; Ma HZ; Gao J; Li P; Tao XJ; Yuan FH; Li J; Yao C; Liu X
J Ethnopharmacol; 2012 Feb; 139(3):757-64. PubMed ID: 22178174
[TBL] [Abstract][Full Text] [Related]
9. Add-on astragalus in type 2 diabetes and chronic kidney disease: A multi-center, assessor-blind, randomized controlled trial.
Chan KW; Kwong ASK; Tsui PN; Chan GCW; Choi WF; Yiu WH; Cheung SCY; Wong MMY; Zhang ZJ; Tan KCB; Lao L; Lai KN; Tang SCW;
Phytomedicine; 2024 Jul; 130():155457. PubMed ID: 38810556
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
Susantitaphong P; Nakwan S; Peerapornratana S; Tiranathanagul K; Katavetin P; Srisawat N; Praditpornsilpa K; Eiam-Ong S
BMC Nephrol; 2017 Jan; 18(1):19. PubMed ID: 28088187
[TBL] [Abstract][Full Text] [Related]
11. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
Inrig JK; Barnhart HX; Reddan D; Patel UD; Sapp S; Califf RM; Singh AK; Szczech LA
Am J Kidney Dis; 2012 Sep; 60(3):390-401. PubMed ID: 22537421
[TBL] [Abstract][Full Text] [Related]
12. Routinely measured iohexol glomerular filtration rate versus creatinine-based estimated glomerular filtration rate as predictors of mortality in patients with advanced chronic kidney disease: a Swedish Chronic Kidney Disease Registry cohort study.
Methven S; Gasparini A; Carrero JJ; Caskey FJ; Evans M
Nephrol Dial Transplant; 2017 Apr; 32(suppl_2):ii170-ii179. PubMed ID: 28339801
[TBL] [Abstract][Full Text] [Related]
13. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
Gan J; Wu Y; Gong X; Ma Y; Yu S; Gao J
Trials; 2019 Aug; 20(1):481. PubMed ID: 31391092
[TBL] [Abstract][Full Text] [Related]
14. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.
McCallum W; Tighiouart H; Ku E; Salem D; Sarnak MJ
Am J Kidney Dis; 2020 Jan; 75(1):21-29. PubMed ID: 31303349
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
[TBL] [Abstract][Full Text] [Related]
16. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
[TBL] [Abstract][Full Text] [Related]
17. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
Goicoechea M; Garcia de Vinuesa S; Verdalles U; Verde E; Macias N; Santos A; Pérez de Jose A; Cedeño S; Linares T; Luño J
Am J Kidney Dis; 2015 Apr; 65(4):543-9. PubMed ID: 25595565
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the Fu-Zheng-Qu-Zhuo method on retarding the progress of chronic kidney disease (stage 3-4): a systematic review and meta-analysis.
Liu SY; Huang P; Zhang N
Ann Transl Med; 2019 Mar; 7(6):114. PubMed ID: 31032269
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study.
Zheng Y; Cai GY; He LQ; Lin HL; Cheng XH; Wang NS; Jian GH; Liu XS; Liu YN; Ni ZH; Fang JA; Ding HL; Guo W; He YN; Wang LH; Wang YP; Yang HT; Ye ZM; Yu RH; Zhao LJ; Zhou WH; Li WG; Mao HJ; Zhan YL; Hu Z; Yao C; Wei RB; Chen XM
Chin Med J (Engl); 2017 Oct; 130(20):2402-2409. PubMed ID: 29052559
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
Zhang L; Li P; Xing CY; Zhao JY; He YN; Wang JQ; Wu XF; Liu ZS; Zhang AP; Lin HL; Ding XQ; Yin AP; Yuan FH; Fu P; Hao L; Miao LN; Xie RJ; Wang R; Zhou CH; Guan GJ; Hu Z; Lin S; Chang M; Zhang M; He LQ; Mei CL; Wang L; Chen X
Am J Kidney Dis; 2014 Jul; 64(1):57-65. PubMed ID: 24631042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
